Saturday 17 October 2026
Export BFRI’s income statement to Excel — free account
Biofrontera Inc.
BFRI Healthcare Drug Manufacturers Specialty & Generic
Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.9%, EPS grew 91.2%, free cash flow grew 45.6% and total debt rose 6.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
0.82
0.03
−3.53%
Follow BFRI
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 2 | 1 | 3 | 4 | 3 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 28.17 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | (1.50) | (1.87) | (6.13) | (7.64) | (5.67) |
P/S ratio |
— | 1.94 | 1.94 | 2.75 | 0.62 | 0.13 | 0.16 | 0.14 |
Altman Z″-Score (non-manufacturers) |
— | (8.26) | (3.78) | (3.71) | (3.75) | (15.70) | (19.71) | (15.24) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (28.99) | (28.99) | (3.16) | (2.16) | (0.49) | (5.91) | (2.44) |
Beneish M-Score |
— | — | (2.20) | (1.72) | (1.46) | (2.02) | (4.32) | 0.02 |
P/B ratio |
— | 0.00 | 0.00 | 5.84 | 0.75 | 0.90 | 1.36 | 0.55 |
Price to Tangible BV |
— | 0.00 | 0.00 | 8.40 | 0.86 | 2.00 | 1.37 | 0.74 |
EV/Sales |
— | 1.85 | 1.85 | 1.73 | (0.30) | 0.22 | 0.12 | 0.10 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.49 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (5.25) | (5.25) | (1.56) | 0.53 | (0.30) | (0.44) | (0.32) |
EV/FCF |
— | (5.25) | (5.25) | (1.56) | 0.53 | (0.30) | (0.44) | (0.32) |
Quick Ratio |
— | 1.03 | 2.57 | 2.67 | 1.68 | 0.36 | 0.93 | 1.15 |
Current Ratio |
— | 2.00 | 4.43 | 3.36 | 2.06 | 1.28 | 1.72 | 1.52 |
Net Debt/EBITDA |
— | (2.17) | 0.89 | 1.00 | 1.52 | (0.11) | 0.11 | 0.17 |
Debt/Assets |
0.00% | 132.86% | 0.00% | 0.00% | 2.65% | 13.98% | 18.54% | 16.07% |
Debt/Equity |
— | (1.27) | 0.00 | 0.00 | 0.06 | 0.81 | 0.92 | 0.44 |
Asset Turnover |
— | 1.82 | 0.71 | 0.62 | 0.55 | 0.86 | 1.49 | 1.65 |
Operating CF/Net income |
— | 3.43 | 1.13 | 0.71 | 25.31 | 1.24 | 0.58 | 1.27 |
Capex/Depreciation |
— | 0.00 | 0.00 | (0.02) | (0.03) | 0.00 | (0.05) | 0.00 |
Interest Coverage |
— | (13.98) | (3.35) | (73.26) | (95.29) | (48.46) | (8.46) | (25.11) |
| — | 90.20% | 90.24% | (439.39%) | (3.63%) | (140.43%) | (384.98%) | (141.30%) | |
| — | (76.39%) | (41.55%) | (97.50%) | (1.23%) | (51.08%) | (70.99%) | (41.59%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | (194.79%) | (410.70%) | (81.82%) |
Return on Tangible Assets |
— | (89.80%) | (70.77%) | (114.80%) | (2.85%) | (393.11%) | (202.75%) | (126.24%) |
Average Days of Receivables |
— | 66.72 | 63.69 | 188.27 | 94.27 | 55.30 | 51.98 | 63.81 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.23% | 5.60% | 8.92% |
Selling, General and Administrative Expense of Revenue |
— | 107.05% | 96.12% | 154.39% | 125.10% | 114.84% | 90.66% | 92.00% |
Intangible Assets out of Total Assets |
0.00 | 0.15 | 0.16 | 0.06 | 0.06 | 0.09 | 0.00 | 0.09 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.54% | 6.46% | 3.07% | 2.73% | 2.28% |
Graham Net Nets |
— | (0.64) | (0.64) | 0.07 | 0.90 | (0.01) | 0.50 | 0.00 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 17.46 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (67,752.82%) | (67,752.82%) | (55.71%) | 3.55% | (565.00%) | (295.12%) | (180.70%) |
Free Cash Flow Yield |
— | (18.11%) | (18.11%) | (40.35%) | (90.90%) | (575.11%) | (170.97%) | (230.48%) |
Revenue per Share |
— | 43.13 | 17,135.45 | 54.72 | 27.13 | 22.03 | 6.77 | 4.10 |
Operating CF per Share |
— | (62.07) | (11,244.55) | (60.66) | (15.33) | (16.10) | (1.86) | (1.31) |
Capex per Share |
— | 0.00 | 0.00 | (0.02) | (0.04) | 0.00 | (0.01) | 0.00 |
Free Cash Flow per Share |
— | (62.07) | (11,244.55) | (60.69) | (15.36) | (16.10) | (1.87) | (1.31) |
Cash per Share |
— | 12.03 | 7,345.45 | 55.73 | 26.26 | 0.92 | 1.07 | 0.63 |
Shareholders Equity per Share |
— | (49.72) | 5,298.18 | 25.74 | 22.59 | 3.10 | 0.80 | 1.03 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (49.72) | 5,298.18 | 25.74 | 22.59 | 3.10 | 0.80 | 1.03 |
Free Cash Flow |
— | (37.68) | (12.37) | (26.73) | (16.24) | (24.90) | (10.33) | (13.36) |
Working Capital |
— | 11.73 | 15.16 | 32.59 | 22.25 | 4.99 | 8.68 | 6.19 |
Capital Expenditures |
— | (0.54) | — | (0.01) | (0.04) | 0.00 | (0.06) | 0.00 |
Net Current Asset Value |
— | (35.46) | 1.27 | 4.54 | 16.13 | (0.06) | 3.03 | 0.00 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.46 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 1.33 | 1.52 | 2.02 | 5.75 | 7.94 | 14.36 | 0.40 |
Cash ROIC |
— | (245.89%) | (88.93%) | (74.48%) | (30.65%) | (246.10%) | (71.52%) | (62.24%) |
Accounts Receivable Turnover |
— | 6.48 | 4.67 | 3.07 | 2.89 | 5.42 | 7.12 | 6.62 |
Accounts Payable Turnover |
— | 2.74 | 1.90 | 9.60 | 8.60 | 3.01 | 2.30 | 1.58 |
Inventory Turnover |
— | 1.49 | 1.03 | 2.21 | 2.61 | 1.93 | 2.12 | 2.72 |
Average Days of Payables |
— | 218.13 | 69.01 | 26.93 | 62.26 | 188.44 | 141.24 | 221.92 |
Days of Inventory on Hand |
— | 292.56 | 285.49 | 127.70 | 172.30 | 228.24 | 130.37 | 47.47 |
Average Receivables |
— | 4.04 | 4.04 | 7.86 | 9.92 | 6.28 | 5.24 | 6.30 |
Average Payables |
— | 4.76 | 4.76 | 1.33 | 1.77 | 5.80 | 8.10 | 6.93 |
Average Inventory |
— | 8.79 | 8.79 | 5.77 | 5.81 | 9.04 | 8.78 | 4.04 |
Average Assets |
— | 14.38 | 26.45 | 38.68 | 52.05 | 39.41 | 25.02 | 25.33 |
Average Common Equity |
— | (12.18) | (12.18) | 8.58 | 17.61 | 14.34 | 4.61 | 7.46 |
Columns are period end dates